PDS Biotechnology Corp — Director's Dealing 2019

Mar 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2019-03-15

Reporting Person: Leuthner Brian A (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-15	Common Stock	M	169032	—	Acquired	239268	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-15	Restricted Stock Units	$	M	169032	Disposed		Common Stock (169032)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8493.85	Indirect
Common Stock	162000	Indirect
Common Stock	223622	Indirect

Footnotes

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: Reflects periodic contributions to the issuer's common stock fund in the issuer's 401(K) Plan as of December 28, 2018. This amendment is being filed to include these shares of the issuer's common stock that were omitted in the prior report.

F3: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F4: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F5: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F6: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F7: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.